Skip to main content

Table 1 Baseline characteristics of the total population and according to randomized groups

From: Gut related inflammation and cardiorespiratory fitness in patients with CAD and type 2 diabetes: a sub-study of a randomized controlled trial on exercise training

  All (n = 137) Exercise (n = 52) Control (n = 62)
Age (years)a 64 [41, 81] 65 [48, 81] 65 [41, 77]
Sex (male) n, (%) 115 (83.9) 45 (86.5) 50 (80.6)
BMIb (kg/m2) 28.7 (25.6, 31.6) 29.4 (25.6, 31.8) 28.3 (25.4, 31.5)
Duration of diabetes (years) 9 (5, 15) 11 (5, 15) 9 (5, 13)
Previous MIc, n (%) 62 (45.3) 20 (38.5) 31 (50.0)
Microvascular complicationsd 26 (19) 7 (13.5) 10 (16.1)
Advanced vascular diseasee, n (%) 85 (62.0) 28 (53.8) 40 (64.4)
Hypertension, n (%) 100 (73.0) 39 (75.0) 46 (74.2)
Current smokers, n (%) 23 (16.8) 9 (17.3) 9 (14.5)
HbA1c (%) 7.4 (6.8, 8.3) 7.4 (6.8, 8.4) 7.3 (6.8, 7.9)
Fasting blood glucose 8.1 (6.9, 9.8) 7.5 (6.7, 9.9) 8.0 (6.8, 9.6)
HOMA2-IRf 1.3 (0.7, 2.1) 1.1 (0.7, 1.9) 1.3 (0.7, 2.2)
Total cholesterol (mmol/L) 3.9 (3.4, 4.5) 3.8 (3.4, 4.3) 4 (3.3, 4.7)
Triglycerides (mmol/L) 1.4 (1.0, 1.9) 1.4 (1.1, 1.9) 1.4 (1.0, 1.9)
LDLg cholesterol (mmol/L) 2.0 (1.6, 2.6) 1.8 (1.5, 2.5) 2.1 (1.6, 2.7)
CRPh (mg/L) 2.6 (1.2, 5.0) 2.0 (0.9, 4.9) 2.4 (1.2, 5.0)
Medication
 RAAS inhibitors, n (%) 97 (70.8) 34 (65.4) 46 (74.2)
 Statins, n (%) 128 (93.4) 49 (94.2) 58 (93.5)
 Metformin, n (%) 101 (73.7) 40 (76.9) 46 (74.2)
 Sulfonylureas, n (%) 48 (35.0) 23 (44.2) 17 (27.4)
 Gliptin, n (%) 17 (12.4) 6 (11.5) 11 (17.7)
 Insulin, n (%) 26 (19.0) 10 (19.2) 12 (19.4)
 Antiplatelet medication, n (%) 129 (94.2) 47 (90.4) 61 (98.4)
  1. Data are presented as median (25, 75 percentiles) if not stated otherwise
  2. aMedian [min, max]
  3. bBody mass index
  4. cMyocardial infarction
  5. dMicrovascular complications were defined as a history of nephron-, neuro- or retinopathy, and/or abnormal monofilament test and/or (micro-) albuminuria
  6. eAdvanced vascular disease was defined as patients having previous myocardial infarction and/or diabetic microvascular complications in addition to coronary artery disease
  7. fGlucose and insulin values were entered in the computer model to calculate HOMA2-IR
  8. gLow-density lipoprotein
  9. hC-reactive protein
\